Salivary duct carcinoma (SDC) is a highly aggressive but very rare malignancy, estimated to represent approximately 1% to 3% of all salivary malignancies
1-3 (up to 6% in one Finnish study). It was first described by Kleinsasser et al
4 in 1968 owing to its histologic similarity to ductal carcinoma of the breast. It occurs predominately in the parotid gland, and most patients die within 3 years, with overall survival (OS) reported as low as 42% for stage I disease and 23% for stage IV disease.
5 Similar to its breast cancer counterpart, many of these tumors overexpress erb-B2, which has been reported to be a negative prognostic indicator.
6-8 The mainstay of therapy is surgery and radiation therapy, but good control remains challenging.
9,10